{
    "clinical_study": {
        "@rank": "112841", 
        "brief_summary": {
            "textblock": "To determine the objective tumor response and remission rate of AIDS-related Kaposi's\n      sarcomas (KS) following a single dose of tin ethyl etiopurpurin (SnET2) followed by\n      photodynamic therapy (PDT). To determine the systemic and local toxicity, and morbidity\n      safety profile of SnET2-PDT."
        }, 
        "brief_title": "Photodynamic Therapy Clinical Trial For Cutaneous AIDS-Related Kaposi's Sarcoma Study Summary.", 
        "condition": [
            "Sarcoma, Kaposi", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Sarcoma, Kaposi", 
                "AIDS-Related Opportunistic Infections", 
                "Sarcoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "All patients receive a single dose of SnET2 and are randomized to receive either PDT light\n      treatment or no light treatment (control group). Patients are assessed prior to and at 4, 12\n      and 24 weeks following treatment, and are followed for 7 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  Documentation of at least one biopsy-confirmed KS lesion.\n\n          -  A minimum of 4 and no more than 36 KS lesions.\n\n          -  All eligible lesions must be bidimensionally measurable, treatable by surface\n             (non-contact) light illumination, and <= 40 mm in diameter of the longest\n             bidimensional axis.\n\n          -  ACTG disease state T(0) L(0) or (1) S(0) or (1).\n\n          -  Life expectancy greater than 6 months.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n          -  Active opportunistic infection or condition except thrush or herpes simplex virus\n             infections.\n\n          -  Advanced KS tumor stages including the presence of tumor associated edema or\n             ulceration, extensive oral KS, or KS in other non-nodal viscera.\n\n          -  Hematopoietic dysfunction.\n\n          -  Coagulation dysfunction.\n\n          -  Hepatic dysfunction.\n\n          -  Renal dysfunction.\n\n          -  Cardiovascular dysfunction - Presence of significant coronary artery disease\n             requiring current treatment or  myocardial infarction.\n\n          -  Pulmonary dysfunction.\n\n          -  Sepsis.\n\n          -  Known disorder of lipoprotein metabolism or clearance.\n\n        Patients with the following prior conditions are excluded:\n\n          -  History of allergic or hypersensitivity reactions to light, egg proteins or egg\n             yolks, history of porphyria, systemic lupus erythematosus or xeroderma pigmentosum.\n\n        Excluded within 7 days of therapy:\n\n          -  Hematopoietic dysfunction.\n\n          -  Coagulation dysfunction.\n\n          -  Hepatic dysfunction.\n\n          -  Renal dysfunction.\n\n        Excluded within 3 months of therapy:\n\n          -  Pulmonary dysfunction.\n\n        Excluded within 6 months of therapy:\n\n          -  Myocardial infarction.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Intralesional chemotherapy within the past 12 weeks.\n\n          -  Systemic chemotherapy or investigational drugs within the past 4 weeks.\n\n        Prior Treatment:\n\n        Excluded within 3 months prior to therapy:\n\n          -  Local cryotherapy or surgery to study lesions.\n\n          -  Systemic or topical photodynamic therapy agents."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "78", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002167", 
            "org_study_id": "261A"
        }, 
        "intervention": {
            "intervention_name": "Tin ethyl etiopurpurin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Radiation-Sensitizing Agents", 
                "Tin etiopurpurin"
            ]
        }, 
        "keyword": [
            "Skin Neoplasms", 
            "Sarcoma, Kaposi", 
            "Acquired Immunodeficiency Syndrome", 
            "Photochemotherapy", 
            "tin etiopurpurin", 
            "Radiation-Sensitizing Agents"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90048"
                    }, 
                    "name": "Cedars Sinai Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90033"
                    }, 
                    "name": "Univ of Southern California / Los Angeles"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94143"
                    }, 
                    "name": "Univ of California / San Francisco / Dermatology"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Denver", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80218"
                    }, 
                    "name": "Health One - Rocky Mountain Cancer Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Buffalo", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14203"
                    }, 
                    "name": "Buffalo Gen Hosp / PDT Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Knoxville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37916"
                    }, 
                    "name": "Thompson Cancer Survival Ctr"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Photodynamic Therapy Clinical Trial For Cutaneous AIDS-Related Kaposi's Sarcoma Study Summary.", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002167"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Clinical Solutions", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 1999"
    }, 
    "geocoordinates": {
        "Buffalo Gen Hosp / PDT Ctr": "42.886 -78.878", 
        "Cedars Sinai Med Ctr": "34.052 -118.244", 
        "Health One - Rocky Mountain Cancer Ctr": "39.739 -104.985", 
        "Thompson Cancer Survival Ctr": "35.961 -83.921", 
        "Univ of California / San Francisco / Dermatology": "37.775 -122.419", 
        "Univ of Southern California / Los Angeles": "34.052 -118.244"
    }
}